Device Trial Radar · NCT03579875
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 13, 2018
Primary completion
Jan 1, 2027
Study completion Jan 5, 2029
Sponsor
- Lead sponsor
- Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
Conditions
- Fanconi Anemia
- Severe Aplastic Anemia
- Myelodysplastic Syndromes
- T Cell Receptor Alpha/Beta Depletion
- Telomere Biology Disorder
- Bone Marrow Failure
- Dyskeratosis Congenita
- Telomere Biology Disorders
Interventions
Total Body Irradiation (TBI) (Plan 1)Drug
300 cGy with thymic shielding on day -6
Cyclophosphamide (CY) (Plan 1)Drug
10 mg/kg IV daily on days -5, -4, -3, and -2
Fludarabine (FLU)Drug
35 mg/m2 IV daily on days -5, -4, -3, and -2
Methylprednisolone (MP)Drug
1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
Donor mobilized PBSC infusionDevice
T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
G-CSFDrug
Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)
Cyclophosphamide (CY) (Plan 2)Drug
5 mg/kg IV daily on days -5, -4, -3, and -2
RituximabDrug
200 mg/m2 IV once on day -1
BusulfanDrug
Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
AlemtuzumabDrug
Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
MelphalanDrug
If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
RituximabDrug
Rituximab will be given once on treatment plans 1-3 on day -1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grade II-IV acute graft versus host disease (GVHD)Time frame: Day 100
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.